ID   A2780/m248
AC   CVCL_A5AD
DR   cancercelllines; CVCL_A5AD
DR   Wikidata; Q107113319
RX   PubMed=9924699;
CC   Population: African American.
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Transfected with: HGNC; 11998; TP53 (with p.Arg248Trp).
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=9924699; DOI=10.1097/00002371-199901000-00007;
RA   Sleijfer S., Le T.K.P., de Jong S., Timmer-Bosscha H., Withoff S.,
RA   Mulder N.H.;
RT   "Combined cytotoxic effects of tumor necrosis factor-alpha with
RT   various cytotoxic agents in tumor cell lines that are drug resistant
RT   due to mutated p53.";
RL   J. Immunother. 22:48-53(1999).
//